Specifically, 42.5% of BC patients (187/440) presented Luminal A cancers, 28.9% (127/440) Luminal B Human Epidermal Growth Factor Receptor 2 (HER2) negative ones, 13.6% (60/440) Luminal B HER2 positive neoplasms, 6.6% (29/440) the hormone receptor (HR) negative HER2 positive subtype, and 8.2% (36/440) were diagnosed with triple-negative BC (TNBC). Here, NR4A1 is linked to breast cancer.